Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Helicobacter pyloriin First Nations and Recent Immigrant Populations in Canada

(2016) Nicola L Jones et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation

(2015) Hideki Mori et al.   HELICOBACTER

Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study

(2015) Hideki Mori et al.   United European Gastroenterology Journal

Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population

(2014) Stephanie Albin et al.   ALLERGY AND ASTHMA PROCEEDINGS

Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy

(2014) Javier P. Gisbert et al.   DIGESTIVE DISEASES AND SCIENCES

Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin

(2014) Takahisa Furuta et al.   INTERNAL MEDICINE

Changes in the first lineHelicobacter pylorieradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (TokyoHelicobacter pyloristudy group)

(2014) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Trends of Second-Line Eradication Therapy forHelicobacter pyloriin Japan: A Multicenter Study in the Tokyo Metropolitan Area

(2013) Daisuke Asaoka et al.   HELICOBACTER

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

(2013) Kazunari Murakami et al.   JOURNAL OF GASTROENTEROLOGY

Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan

(2013) Takahisa Furuta et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Helicobacter pylori Resistance to Rifabutin in the Last 7 Years

(2011) Toshihiro Nishizawa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

(2011) Juntaro Matsuzaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genotypic Resistance inHelicobacter pyloriStrains Correlates with Susceptibility Test and Treatment Outcomes after Levofloxacin- and Clarithromycin-Based Therapies

(2010) Jyh-Ming Liou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Helicobacter pylorieradication therapy

(2010) Hidekazu Suzuki et al.   Future Microbiology

Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin

(2010) Makoto Sasaki et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy

(2010) Juntaro Matsuzaki et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Self-reported Antibiotic Allergy Incidence and Prevalence: Age and Sex Effects

(2009) Eric Macy et al.   AMERICAN JOURNAL OF MEDICINE

Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin

(2009) J.P. Gisbert et al.   DIGESTIVE AND LIVER DISEASE